Symbols / QTRX Stock $3.09 -1.28% Quanterix Corporation

Healthcare • Medical Devices • United States • NGM
QTRX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Medical Devices
CEO Mr. Everett V. Cunningham
Exch · Country NGM · United States
Market Cap 145.56M
Enterprise Value 81.63M
Income -104.19M
Sales 144.98M
FCF (ttm) -21.98M
Book/sh 6.00
Cash/sh 2.11
Employees 450
Insider 10d —
IPO Dec 07, 2017
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -2.27
PEG —
P/S 1.00
P/B 0.52
P/C —
EV/EBITDA -1.28
EV/Sales 0.56
Quick Ratio 2.54
Current Ratio 3.72
Debt/Eq 12.52
LT Debt/Eq —
EPS (ttm) -2.35
EPS next Y -1.36
EPS Growth —
Revenue Growth 20.10%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-06
Earnings (prior) 2026-05-06
ROA -13.39%
ROE -34.81%
ROIC —
Gross Margin 45.31%
Oper. Margin -59.12%
Profit Margin -71.86%
Shs Outstand 47.11M
Shs Float 38.49M
Insider Own 6.29%
Instit Own 85.44%
Short Float 12.09%
Short Ratio 3.34
Short Interest 5.06M
52W High 8.77
vs 52W High -64.77%
52W Low 2.40
vs 52W Low 29.02%
Beta 1.12
Impl. Vol. 25.00%
Rel Volume 0.73
Avg Volume 1.13M
Volume 817.45K
Target (mean) $4.33
Tgt Median $4.00
Tgt Low $4.00
Tgt High $5.00
# Analysts 3
Recom Hold
Prev Close $3.13
Price $3.09
Change -1.28%
About

Quanterix Corporation, a life sciences company in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, the company offers contract research and clinical laboratory testing services, including research and clinical trial testing, and lucent diagnostic services. The company primarily operates in the areas of neurology, oncology and immunology, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and sales force and distributors. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$4.33
Mean price target
2. Current target
$3.09
Latest analyst target
3. DCF / Fair value
$-8.40
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.09
Low
$4.00
High
$5.00
Mean
$4.33

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-07 main TD Cowen Hold → Hold $4
2026-04-20 main Canaccord Genuity Hold → Hold $4
2025-12-22 main Canaccord Genuity Hold → Hold $8
2025-08-11 down Canaccord Genuity Buy → Hold $5
2025-05-13 main Canaccord Genuity Buy → Buy $12
2025-04-30 down Leerink Partners Outperform → Market Perform $8
2025-03-25 main Scotiabank Sector Outperform → Sector Outperform $18
2025-03-18 main Canaccord Genuity Buy → Buy $15
2024-11-13 main TD Cowen Hold → Hold $16
2024-08-12 main Scotiabank Sector Outperform → Sector Outperform $28
2024-08-09 main TD Cowen Hold → Hold $15
2024-07-09 main Goldman Sachs Buy → Buy $24
2024-04-29 main Canaccord Genuity Buy → Buy $25
2024-03-04 main Scotiabank Sector Outperform → Sector Outperform $32
2023-09-28 main Goldman Sachs Buy → Buy $34
2023-09-27 main Goldman Sachs Buy → Buy $34
2023-09-25 up Canaccord Genuity Hold → Buy $32
2023-08-09 main Goldman Sachs Buy → Buy $30
2023-05-24 main Goldman Sachs Buy → Buy $27
2023-05-23 up Goldman Sachs Neutral → Buy $27
News
RSS: Latest QTRX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-05-29 MILLER MICHAEL FRANCIS Chief Technology Officer — 130 — —
2026-05-15 SRIRAM VANDANA Chief Financial Officer — 1,833 — —
2026-05-15 MILLER MICHAEL FRANCIS Chief Technology Officer — 1,558 — —
2026-04-30 MILLER MICHAEL FRANCIS Chief Operating Officer — 130 — —
2026-04-15 SRIRAM VANDANA Chief Financial Officer — 1,833 — —
2026-04-15 MILLER MICHAEL FRANCIS Chief Operating Officer — 1,558 — —
2026-04-01 MENDEL SCOTT Director — 4,310 $0.00 $0
2026-04-01 DONNELLY WILLIAM P Officer and Director — 6,178 $0.00 $0
2026-03-31 MILLER MICHAEL FRANCIS Chief Operating Officer — 229 — —
2026-03-13 SRIRAM VANDANA Chief Financial Officer — 1,833 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
138.65
+2.38%
135.44
+11.80%
121.14
+15.42%
104.95
Operating Revenue
138.65
+2.38%
135.44
+11.80%
121.14
+15.42%
104.95
Cost Of Revenue
73.94
+36.12%
54.32
+12.82%
48.14
-19.97%
60.16
Reconciled Cost Of Revenue
73.94
+36.12%
54.32
+12.82%
48.14
-19.97%
60.16
Gross Profit
64.72
-20.22%
81.12
+11.13%
73.00
+62.96%
44.79
Operating Expense
174.53
+30.51%
133.74
+13.66%
117.66
-1.54%
119.50
Research And Development
35.92
+15.57%
31.08
+19.25%
26.06
-2.78%
26.81
Selling General And Administration
138.85
+32.70%
104.64
+12.73%
92.82
-0.47%
93.26
Selling And Marketing Expense
—
—
—
92.00
General And Administrative Expense
138.85
+32.70%
104.64
+12.73%
92.82
-0.47%
93.26
Other Gand A
138.01
+35.81%
101.62
+14.04%
89.11
-2.98%
91.85
Other Operating Expenses
-0.24
+87.76%
-1.99
-61.51%
-1.23
-115.61%
-0.57
Total Expenses
248.47
+32.13%
188.05
+13.42%
165.80
-7.71%
179.66
Operating Income
-109.81
-108.71%
-52.62
-17.81%
-44.66
+40.22%
-74.71
Total Operating Income As Reported
-125.54
-138.60%
-52.62
-14.40%
-45.99
+55.89%
-104.26
EBITDA
-90.89
-105.35%
-44.26
-21.68%
-36.37
+46.97%
-68.58
Normalized EBITDA
-79.71
-80.09%
-44.26
-26.29%
-35.05
+10.21%
-39.03
Reconciled Depreciation
18.93
+126.48%
8.36
+0.80%
8.29
+35.37%
6.12
EBIT
-109.81
-108.71%
-52.62
-17.81%
-44.66
+40.22%
-74.71
Total Unusual Items
-11.18
0.00
+100.00%
-1.33
+95.51%
-29.56
Total Unusual Items Excluding Goodwill
-11.18
0.00
+100.00%
-1.33
+95.51%
-29.56
Special Income Charges
-11.18
0.00
+100.00%
-1.33
+95.51%
-29.56
Impairment Of Capital Assets
15.73
0.00
-100.00%
1.33
-95.51%
29.56
Restructuring And Mergern Acquisition
-4.55
0.00
0.00
-100.00%
3.75
Net Income
-107.15
-178.09%
-38.53
-35.89%
-28.35
+71.52%
-99.57
Pretax Income
-112.27
-194.70%
-38.10
-37.86%
-27.64
+72.20%
-99.41
Net Non Operating Interest Income Expense
8.57
-41.54%
14.65
-7.48%
15.84
+208.69%
5.13
Net Interest Income
8.57
-41.54%
14.65
-7.48%
15.84
+208.69%
5.13
Interest Income Non Operating
8.57
-41.54%
14.65
-7.48%
15.84
+208.69%
5.13
Interest Income
8.57
-41.54%
14.65
-7.48%
15.84
+208.69%
5.13
Other Income Expense
-11.02
-8005.15%
-0.14
-111.44%
1.19
+103.99%
-29.83
Other Non Operating Income Expenses
0.16
+215.44%
-0.14
-105.40%
2.52
+1008.66%
-0.28
Tax Provision
-5.12
-1279.95%
0.43
-39.64%
0.72
+338.41%
0.16
Tax Rate For Calcs
0.00
-78.10%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
-0.51
0.00
+100.00%
-0.28
+95.51%
-6.21
Net Income Including Noncontrolling Interests
-107.15
-178.09%
-38.53
-35.89%
-28.35
+71.52%
-99.57
Net Income From Continuing Operation Net Minority Interest
-107.15
-178.09%
-38.53
-35.89%
-28.35
+71.52%
-99.57
Net Income From Continuing And Discontinued Operation
-107.15
-178.09%
-38.53
-35.89%
-28.35
+71.52%
-99.57
Net Income Continuous Operations
-107.15
-178.09%
-38.53
-35.89%
-28.35
+71.52%
-99.57
Normalized Income
-96.48
-150.41%
-38.53
-41.11%
-27.30
+64.18%
-76.22
Net Income Common Stockholders
-107.15
-178.09%
-38.53
-35.89%
-28.35
+71.52%
-99.57
Diluted EPS
-2.51
-151.00%
-1.00
-33.33%
-0.75
+71.26%
-2.61
Basic EPS
-2.51
-151.00%
-1.00
-33.33%
-0.75
+71.26%
-2.61
Basic Average Shares
42.64
+11.13%
38.37
+2.06%
37.59
+1.63%
36.99
Diluted Average Shares
42.64
+11.13%
38.37
+2.06%
37.59
+1.63%
36.99
Diluted NI Availto Com Stockholders
-107.15
-178.09%
-38.53
-35.89%
-28.35
+71.52%
-99.57
Rent And Landing Fees
0.84
-72.05%
3.02
-18.64%
3.71
+163.08%
1.41
Rent Expense Supplemental
0.84
-72.05%
3.02
-18.64%
3.71
+163.08%
1.41
Total Other Finance Cost
—
—
-15.84
-208.69%
-5.13
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
418.77
+3.01%
406.53
-5.14%
428.57
-1.16%
433.58
Current Assets
212.26
-41.62%
363.59
-4.84%
382.10
+0.15%
381.52
Cash Cash Equivalents And Short Term Investments
118.23
-59.11%
289.12
-10.02%
321.32
-5.14%
338.74
Cash And Cash Equivalents
29.84
-47.38%
56.71
-67.49%
174.42
-48.51%
338.74
Cash Equivalents
17.22
-61.24%
44.43
-72.62%
162.26
-46.99%
306.10
Cash Financial
12.62
+2.74%
12.28
+0.99%
12.16
-62.74%
32.64
Other Short Term Investments
88.39
-61.97%
232.41
+58.21%
146.90
0.00
Receivables
29.97
-6.75%
32.14
+26.47%
25.41
+33.64%
19.02
Accounts Receivable
29.97
-6.75%
32.14
+26.47%
25.41
+33.64%
19.02
Gross Accounts Receivable
32.34
-2.54%
33.18
+28.28%
25.87
+35.19%
19.14
Allowance For Doubtful Accounts Receivable
-2.37
-127.26%
-1.04
-129.52%
-0.45
-284.75%
-0.12
Inventory
54.76
+67.09%
32.77
+25.46%
26.12
+53.99%
16.96
Raw Materials
13.73
+90.26%
7.21
+41.08%
5.11
-7.17%
5.51
Work In Process
11.03
+38.22%
7.98
+46.72%
5.44
+59.27%
3.42
Finished Goods
30.01
+70.68%
17.58
+12.91%
15.57
+93.66%
8.04
Prepaid Assets
—
—
—
—
Other Current Assets
9.29
-2.78%
9.56
+3.49%
9.23
+35.73%
6.80
Total Non Current Assets
206.51
+380.94%
42.94
-7.60%
46.47
-10.73%
52.06
Net PPE
40.34
+20.45%
33.49
-7.43%
36.18
-11.84%
41.03
Gross PPE
66.16
+26.48%
52.31
+4.01%
50.30
-3.35%
52.04
Accumulated Depreciation
-25.83
-37.20%
-18.82
-33.31%
-14.12
-28.27%
-11.01
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
10.51
+30.75%
8.04
+37.77%
5.83
+8.42%
5.38
Other Properties
39.52
+27.55%
30.99
-1.29%
31.39
-4.80%
32.98
Leases
16.13
+21.38%
13.29
+1.66%
13.07
-4.49%
13.69
Goodwill And Other Intangible Assets
158.16
+3823.67%
4.03
-33.20%
6.03
-19.72%
7.52
Goodwill
26.38
0.00
—
0.00
Other Intangible Assets
131.79
+3169.34%
4.03
-33.20%
6.03
-19.72%
7.52
Other Non Current Assets
8.01
+47.81%
5.42
+27.18%
4.26
+21.47%
3.51
Total Liabilities Net Minority Interest
123.04
+60.84%
76.50
-2.69%
78.61
+3.91%
75.65
Current Liabilities
74.76
+77.98%
42.01
+7.76%
38.98
+24.35%
31.35
Payables And Accrued Expenses
24.27
+53.57%
15.80
+42.34%
11.10
+23.60%
8.98
Payables
14.69
+84.33%
7.97
+35.79%
5.87
+45.95%
4.02
Accounts Payable
13.57
+95.14%
6.95
+37.74%
5.05
+31.60%
3.84
Current Accrued Expenses
9.58
+22.26%
7.83
+49.68%
5.23
+5.48%
4.96
Pensionand Other Post Retirement Benefit Plans Current
14.98
+18.69%
12.62
-10.94%
14.17
+28.41%
11.04
Total Tax Payable
1.12
+10.51%
1.02
+23.84%
0.82
+341.94%
0.19
Current Debt And Capital Lease Obligation
7.92
+66.44%
4.76
+12.14%
4.24
+57.83%
2.69
Current Capital Lease Obligation
7.92
+66.44%
4.76
+12.14%
4.24
+57.83%
2.69
Current Deferred Liabilities
20.73
+134.82%
8.83
-6.77%
9.47
+9.53%
8.64
Current Deferred Revenue
20.73
+134.82%
8.83
-6.77%
9.47
+9.53%
8.64
Other Current Liabilities
6.87
—
—
0.39
Total Non Current Liabilities Net Minority Interest
48.27
+39.97%
34.49
-12.97%
39.63
-10.55%
44.30
Long Term Debt And Capital Lease Obligation
29.32
-10.09%
32.62
-12.38%
37.22
-10.13%
41.42
Long Term Capital Lease Obligation
29.32
-10.09%
32.62
-12.38%
37.22
-10.13%
41.42
Non Current Deferred Liabilities
13.93
+643.57%
1.87
-22.09%
2.40
-16.64%
2.88
Non Current Deferred Revenue
5.83
+443.34%
1.07
-12.55%
1.23
-13.29%
1.42
Non Current Deferred Taxes Liabilities
8.10
+912.13%
0.80
-32.03%
1.18
-19.88%
1.47
Other Non Current Liabilities
5.02
—
—
—
Stockholders Equity
295.73
-10.40%
330.04
-5.69%
349.96
-2.23%
357.93
Common Stock Equity
295.73
-10.40%
330.04
-5.69%
349.96
-2.23%
357.93
Capital Stock
0.05
+20.51%
0.04
+2.63%
0.04
+2.70%
0.04
Common Stock
0.05
+20.51%
0.04
+2.63%
0.04
+2.70%
0.04
Share Issued
46.74
+21.27%
38.54
+1.39%
38.01
+1.97%
37.28
Ordinary Shares Number
46.74
+21.27%
38.54
+1.39%
38.01
+1.97%
37.28
Additional Paid In Capital
873.64
+8.77%
803.16
+2.56%
783.14
+2.56%
763.63
Retained Earnings
-577.23
-22.79%
-470.08
-8.93%
-431.55
-7.03%
-403.20
Gains Losses Not Affecting Retained Earnings
-0.72
+76.53%
-3.08
-84.21%
-1.67
+34.12%
-2.54
Other Equity Adjustments
-0.72
+76.53%
-3.08
-84.21%
-1.67
+34.12%
-2.54
Total Equity Gross Minority Interest
295.73
-10.40%
330.04
-5.69%
349.96
-2.23%
357.93
Total Capitalization
295.73
-10.40%
330.04
-5.69%
349.96
-2.23%
357.93
Working Capital
137.50
-57.24%
321.59
-6.27%
343.11
-2.02%
350.18
Invested Capital
295.73
-10.40%
330.04
-5.69%
349.96
-2.23%
357.93
Total Debt
37.24
-0.35%
37.37
-9.87%
41.46
-5.99%
44.10
Capital Lease Obligations
37.24
-0.35%
37.37
-9.87%
41.46
-5.99%
44.10
Net Tangible Assets
137.57
-57.80%
326.01
-5.21%
343.92
-1.85%
350.42
Tangible Book Value
137.57
-57.80%
326.01
-5.21%
343.92
-1.85%
350.42
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-77.24
-119.65%
-35.16
-86.56%
-18.85
+61.22%
-48.61
Cash Flow From Continuing Operating Activities
-77.24
-119.65%
-35.16
-86.56%
-18.85
+61.22%
-48.61
Net Income From Continuing Operations
-107.15
-178.09%
-38.53
-35.89%
-28.35
+71.52%
-99.57
Depreciation Amortization Depletion
18.93
+126.48%
8.36
+0.80%
8.29
+35.37%
6.12
Depreciation
18.93
+126.48%
8.36
+0.80%
8.29
+35.37%
6.12
Depreciation And Amortization
18.93
+126.48%
8.36
+0.80%
8.29
+35.37%
6.12
Other Non Cash Items
-3.27
-1046.67%
0.34
+146.43%
0.14
+121.84%
-0.64
Stock Based Compensation
20.72
+3.66%
19.99
+18.81%
16.82
+9.36%
15.38
Asset Impairment Charge
8.38
+1325.17%
0.59
-65.35%
1.70
-93.42%
25.80
Deferred Tax
-5.87
-1923.10%
-0.29
+0.00%
-0.29
-28.32%
-0.23
Deferred Income Tax
-5.87
-1923.10%
-0.29
+0.00%
-0.29
-28.32%
-0.23
Operating Gains Losses
—
—
—
-0.21
Net Foreign Currency Exchange Gain Loss
—
—
—
-0.22
Gain Loss On Sale Of PPE
—
—
—
0.01
Change In Working Capital
-6.90
+63.28%
-18.79
-23.67%
-15.19
-453.61%
4.30
Change In Receivables
10.61
+237.71%
-7.70
-15.07%
-6.70
-229.85%
5.16
Changes In Account Receivables
10.61
+237.71%
-7.70
-15.07%
-6.70
-229.85%
5.16
Change In Inventory
4.03
+160.38%
-6.68
+25.32%
-8.94
-223.48%
7.24
Change In Prepaid Assets
3.52
+894.81%
-0.44
+81.32%
-2.37
-221.27%
-0.74
Change In Payables And Accrued Expense
-8.44
-498.02%
2.12
-62.12%
5.60
+163.01%
-8.89
Change In Accrued Expense
-7.91
-666.09%
1.40
-68.30%
4.41
+222.53%
-3.60
Change In Payable
-0.53
-173.03%
0.72
-39.19%
1.19
+122.49%
-5.29
Change In Account Payable
-0.53
-173.03%
0.72
-39.19%
1.19
+122.49%
-5.29
Change In Other Working Capital
-16.87
-246.71%
-4.87
-135.87%
-2.06
-179.38%
2.60
Change In Other Current Assets
0.25
+120.74%
-1.22
-69.46%
-0.72
+12.77%
-0.82
Change In Other Current Liabilities
—
-4.07
-50.93%
-2.70
-953.91%
-0.26
Investing Cash Flow
50.23
+161.06%
-82.27
+44.59%
-148.45
-1238.15%
-11.09
Cash Flow From Continuing Investing Activities
50.23
+161.06%
-82.27
+44.59%
-148.45
-1238.15%
-11.09
Net PPE Purchase And Sale
-2.61
+22.45%
-3.37
+12.31%
-3.84
+66.93%
-11.61
Purchase Of PPE
-2.61
+22.45%
-3.37
+12.31%
-3.84
+66.93%
-11.61
Capital Expenditure
-2.61
+22.45%
-3.37
+12.31%
-3.84
+66.93%
-11.61
Net Investment Purchase And Sale
146.07
+285.14%
-78.90
+45.44%
-144.61
0.00
Purchase Of Investment
-69.76
+76.40%
-295.61
-68.33%
-175.61
0.00
Sale Of Investment
215.83
-0.41%
216.71
+599.06%
31.00
0.00
Net Business Purchase And Sale
-93.23
0.00
0.00
—
Purchase Of Business
-93.23
0.00
0.00
—
Net Other Investing Changes
—
—
—
0.52
Financing Cash Flow
-0.71
-255.26%
0.46
-83.05%
2.69
+16.44%
2.31
Cash Flow From Continuing Financing Activities
-0.71
-255.26%
0.46
-83.05%
2.69
+16.44%
2.31
Net Issuance Payments Of Debt
—
—
0.00
0.00
Repayment Of Debt
—
—
0.00
0.00
Long Term Debt Payments
—
—
0.00
0.00
Net Long Term Debt Issuance
—
—
0.00
0.00
Net Common Stock Issuance
—
—
0.00
0.00
Proceeds From Stock Option Exercised
0.74
-75.93%
3.07
+6.13%
2.89
+25.01%
2.31
Net Other Financing Charges
-1.45
+44.60%
-2.61
-1218.18%
-0.20
—
Changes In Cash
-27.71
+76.31%
-116.97
+28.94%
-164.61
-186.81%
-57.39
Effect Of Exchange Rate Changes
1.57
+314.44%
-0.73
-343.85%
0.30
+155.95%
-0.54
Beginning Cash Position
59.32
-66.49%
177.03
-48.14%
341.34
-14.51%
399.27
End Cash Position
33.18
-44.07%
59.32
-66.49%
177.03
-48.14%
341.34
Free Cash Flow
-79.85
-107.23%
-38.53
-69.82%
-22.69
+62.32%
-60.23
Interest Paid Supplemental Data
—
—
0.00
0.00
Income Tax Paid Supplemental Data
—
0.88
+8.29%
0.81
+18.13%
0.68
Amortization Of Securities
-2.08
+69.59%
-6.83
-247.91%
-1.96
0.00
Common Stock Issuance
—
—
0.00
0.00
Issuance Of Capital Stock
—
—
0.00
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category